Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 15/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 15/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 15/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.35 |
| ▸ | PIM1 | P11309 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29471176 | 1.00 | FGFR1 (0.43) | FGFR1FGFR2FGFR3FGFR4CREBBP | |
| SCHEMBL24316636 | 0.90 | FGFR1 (0.37) | FGFR1FGFR2FGFR3FGFR4CREBBP | |
| SCHEMBL29471227 | 0.90 | FGFR1 (0.37) | FGFR1FGFR2FGFR3FGFR4CREBBP | |
| SCHEMBL24316541 | 0.90 | FGFR2 (0.40) | FGFR1FGFR2FGFR3FGFR4CREBBP | |
| SCHEMBL24316544 | 0.90 | CREBBP (0.35) | FGFR1FGFR2FGFR3FGFR4CREBBP | |
| SCHEMBL24316725 | 0.88 | FGFR4 (0.35) | FGFR1FGFR2FGFR3FGFR4CREBBP | |
| SCHEMBL29471209 | 0.87 | CREBBP (0.37) | FGFR1FGFR2FGFR3FGFR4CREBBP | |
| SCHEMBL26548686 | 0.87 | CREBBP (0.37) | FGFR1FGFR2FGFR3FGFR4CREBBP | |
| SCHEMBL29471151 | 0.87 | CREBBP (0.36) | FGFR1FGFR2FGFR3FGFR4CREBBP | |
| SCHEMBL24316886 | 0.87 | CREBBP (0.36) | FGFR1FGFR2FGFR3FGFR4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-10-12 | — | — | US | disclosed |
| CN-116368128-A | Heterocyclic compounds as CBP/EP300 bromodomain inhibitors | 奥瑞基尼肿瘤有限公司 | 2023-06-30 | — | — | CN | disclosed |
| WO-2022053967-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322724-A1 | HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS | EP300, HDAC1, BRD3 | FGFR1 1849/4885FGFR2 2803/4885FGFR3 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.